EDAP TMS S. A. is a medical technology company focused on the development, manufacturing, marketing, and sale of noninvasive therapeutic ultrasound and energy based medical devices. The company's core technology is high intensity focused ultrasound (HIFU) embodied in its flagship product, the Focal One Robotic HIFU system, which is used primarily in urology for the treatment of prostate cancer and is being expanded to address benign prostatic hyperplasia and endometriosis. EDAP TMS S. A. manufactures and sells its products globally, with headquarters in Vaulx en Velin, France and operations in the United States, Europe, Asia and other international markets. The firm is listed on the Nasdaq Global Market under the ticker EDAP and has realigned its business to concentrate exclusively on HIFU based applications driven by the Focal One platform.

The company generates revenue from the sale of capital equipment, principally the Focal One Robotic HIFU system, and from recurring revenue streams including consumables, maintenance, and service contracts tied to its installed base. In addition, EDAP TMS S. A. markets and supports legacy extracorporeal shock wave lithotripsy (ESWL) systems, accessories, and related services, and distributes third party urology products such as laser, micro ultrasound, and urodynamics devices. The recurring revenue model provides predictable cash flow as the number of installed systems grows over time.

The company operates through the following segments.

• HIFU: This segment develops, manufactures, and sells the Focal One Robotic HIFU system and its consumables, provides maintenance and service support, conducts clinical development for prostate cancer, benign prostatic hyperplasia, and endometriosis indications, and the system features the HIFUsion software for importing MRI, PSMA PET and 3D biopsy maps, a multi axis robotic positioning system with sub millimeter precision, a dynamic focusing probe that combines real time ultrasound imaging with precise HIFU energy delivery, and an integrated cart based workstation designed for ergonomic workflow in the operating room.

• ESWL: This segment markets and supports legacy extracorporeal shock wave lithotripsy systems, accessories, and related services, distributes third party urology products including laser, micro ultrasound, and urodynamics devices, contributes to the installed base, generates service revenue, and maintains long standing relationships with urology customers.

EDAP TMS S. A. holds a niche position in the medical device industry as a pioneer of robotic HIFU for focal therapy, competing against established treatment modalities such as radical prostatectomy, radiation therapy, and cryotherapy, as well as other HIFU providers like Sonablate Corporation, Profound Medical Corp., Insightec Ltd., and Haifu. The company’s competitive advantages stem from its proprietary HIFU technology, a growing body of clinical evidence demonstrating noninferior oncologic outcomes and improved functional preservation, regulatory clearances including CE Marking and FDA 510(k) approvals, a robotic platform with AI enabled software potential, and an expanding reimbursement framework in key markets. Additionally, the firm’s intellectual property portfolio includes 71 granted HIFU patents and 15 granted ESWL patents, providing a barrier to entry and supporting long term innovation.

The company serves academic, public, and private hospitals and clinics worldwide, primarily urologists who treat prostate cancer and other urologic conditions, with an increasing focus on gynecologists for the treatment of endometriosis. No single customer represents a significant portion of the installed base, and sales are distributed across multiple geographic regions including North America, Europe, and Asia.